Netherlands· NL-4822d8428f96
Korjuny 10 microgram concentraat voor oplossing voor infusie
A catumaxomab product containing catumaxomab, registered in Netherlands by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Catumaxomab is registered in 9 of 19 countries.
Countries holding a registration under ATC L01FX03 (catumaxomab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 5 of them publish a price we can compare per daily dose
Catumaxomab · ATC L01FX03
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CATUMAXOMAB
- Manufacturer
- Atnahs Pharma Netherlands B.V.
- Country
- Netherlands (NL)
- ATC code
- L01FX03
- ATC class
- Catumaxomab
- Defined daily dose
- 21 mcg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1826
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Catumaxomab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandKorjunyAtnahs Pharma Netherlands B.V.
- IrelandKorjuny 10 micrograms concentrate for solution for infusionAtnahs Pharma Netherlands B.V.
- SpainKORJUNY 10 MICROGRAMOS CONCENTRADO PARA SOLUCION PARA PERFUSIONAtnahs Pharma Netherlands Bv.
- BelgiumKorjuny 10 µgAtnahs Pharma Netherlands
- IcelandKorjunyAtnahs Pharma Netherlands B.V.
- PolandKORJUNYLindis Biotech GmbH
- SwedenKorjuny 10 mikrogram Koncentrat till infusionsvätska, lösningAtnahs Pharma Netherlands B.V.
- CzechiaKORJUNYAtnahs Pharma Netherlands B.V., Amsterdam
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Korjuny
- Liechtenstein · Korjuny
- Norway · Korjuny
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c448c586-368f-4fe0-8edd-f13c4f3437ef GET /v1/drugs/c448c586-368f-4fe0-8edd-f13c4f3437ef?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraperitoneaal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/korjuny-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Catumaxomab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130326",
"excipients": [
"CITROENZUUR 1-WATER (E 330)",
"POLYSORBAAT 80 (E 433)",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"WATER VOOR INJECTIE"
],
"substances": [
"CATUMAXOMAB"
],
"leaflet_url": null,
"authorised_at": "2025/02/10",
"procedure_number": "EMEA/H/C/005697",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1826",
"additional_monitoring": "N"
}See everything about catumaxomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.